Di Bella Giuseppe, Gualano Luciano, Di Bella Luigi
Di Bella Foundation, Via Guglielmo Marconi 51 Bologna, 40122, Italy.
Private Laboratory of Physiology, Via Stefano Giovanni Marianini, Modena 41123, Italy.
Neuro Endocrinol Lett. 2017 Dec;38(7):465-474.
Melatonin has shown the potential to inhibit growth of different tumors, both in vitro and in vivo. There is clear evidence that the administration of melatonin alone or in combination with chemo and radiotherapy in cancer patients with advanced solid tumors has been associated with improved outcomes of tumor regression and survival. Moreover, chemotherapy has been shown to be better tolerated in patients treated with melatonin. However, there are different ways of preparation and administration of melatonin to the patient. This review article aims to offer the insight into the preparation, biological features and clinical findings in its use in cancer patients. Melatonin (MLT) can only be solubilized in water at 40-45 °C; at other temperatures it can only be solubilized in alcohol. It is absorbed in the human body complexed with adenosine by a hydrogen bond. It acts on two common denominators: proliferation and differentiation; in addition to anticancer homeostasis, MLT has a documented antidegenerative and immunomodulatory role. It also plays an important role in limiting oxidative stress, affecting blood and bone marrow constituent ratio, leukocyte formula regulation, hemoglobin synthesis, platelet genesis, aggregation and in erythrocyte resistance. Despite of all these important roles, most well-known features are probably the least important ones, such as sleep and wakefulness regulation and its effect on jet lag. In the preparation formulated by Prof. Di Bella, melatonin with adenosine at a ratio of 1:4, stabilized with 30% of glycine (MLT-DBM), has been used since 1994 in many patients with various indications and positive therapeutic responses and a total absence of toxicity. This method can be a good alternative to commercially produced preparations, as it was scientifically proved and published worldwide at conferences and in various medical journals.
褪黑素已显示出在体外和体内抑制不同肿瘤生长的潜力。有明确证据表明，在晚期实体瘤癌症患者中单独使用褪黑素或与化疗及放疗联合使用，与肿瘤消退和生存结果的改善相关。此外，已证明接受褪黑素治疗的患者对化疗的耐受性更好。然而，给患者使用褪黑素的制备和给药方式有多种。这篇综述文章旨在深入探讨其在癌症患者中的制备、生物学特性和临床发现。褪黑素（MLT）仅在40 - 45°C的水中可溶解；在其他温度下，它只能溶解于酒精中。它在人体中通过氢键与腺苷结合被吸收。它作用于两个共同因素：增殖和分化；除了抗癌稳态外，MLT还具有已被证实的抗退变和免疫调节作用。它在限制氧化应激、影响血液和骨髓成分比例、调节白细胞分类、血红蛋白合成、血小板生成、聚集以及红细胞抗性方面也发挥着重要作用。尽管有所有这些重要作用，但最广为人知的特性可能是最不重要的，比如睡眠和觉醒调节以及对时差的影响。在迪贝拉教授配制的制剂中，褪黑素与腺苷的比例为1:4，并以30%的甘氨酸稳定（MLT - DBM），自1994年以来已用于许多有各种适应症的患者，且有积极的治疗反应且完全没有毒性。这种方法可以是商业生产制剂的一个很好的替代方案，因为它已得到科学证明并在全球会议和各种医学期刊上发表。
